Conference abstract · 16 Oct 2017
Conference abstractPublished 15 Apr 2019
Sample size in biosimilar drug product development
Center for Drug Evaluation and Research-US FDA, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
For the approval of biosimilar products, the United States Food and Drug Administration (FDA) recommends a stepwise approach for obtaining the totality-of-the-evidence for assessing biosimilarity between a proposed biosimilar product and its corresponding innovative (reference) biologic product. The stepwise approach starts with the assessment of analytical similarity followed by animal studies for toxicity, pharmacokinetics and pharmacodynamics (PK/PD) for pharmacological activities, immunogenicity and clinical studies for safety and efficacy. At each step, study endpoint and similarity margin for demonstration of biosimilarity are different. In this presentation, we will focus on sample size determination at each step of biosimilar product development. For illustration purpose, we will focus on the discussion of the FDAâ??s proposal (by adjusting similarity margin and variability associated with reference product) for selecting an appropriate sample size for analytical similarity assessment in biosimilar product development.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 16 Oct 2017
Interchangeability, switch ability and substitution of biosimilars drug products
Conference abstract
Production of biosimilar protein-based drugs in plant bioreactors
Review article · 26 Jul 2016
Regulatory strategy for the development of analytical methods for the routine determination of aggregate profiles for a biosimilar product
Conference abstract · 25 Sep 2014
Production of biosimilars in developing countries: Challenges and opportunities: SEDICO case Study
More from this journal
The newest in Journal of Bioanalysis & Biomedicine.
Article · 29 Dec 2025
Label-Free Biosensing: Revolutionizing Disease Detection and Drug Discovery
Article · 29 Dec 2025
Epigenetic Modifications: Bioanalysis for Disease and Therapeutics
Article · 29 Dec 2025
Advancing Bioanalysis: New Tech, AI, and Precision Medicine
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioanalysis & Biomedicine
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Shein-Chung Chow”

